|
LYEL | Lyell Immunopharma, Inc. |
|
|
LYEL | Lyell Immunopharma, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 2.47 |
| Leverage | 22.01% |
| Market Cap | $ 155.0m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -338.9m |
| Margin | -7267.74% |
Lyell Immunopharma, Inc., a T-cell reprogramming company, is dedicated to the development of T-cell therapies for patients with solid tumors. The company is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.